<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657367</url>
  </required_header>
  <id_info>
    <org_study_id>R-I- 002/436/2019</org_study_id>
    <nct_id>NCT04657367</nct_id>
  </id_info>
  <brief_title>Polish Registry of Diabetes (PolReD)</brief_title>
  <acronym>PolReD</acronym>
  <official_title>Polish Registry of Diabetes - PL: Polski Rejestr Diabetologiczny (PolReD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Bialystok</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to create a registry of diabetic patients, containing a detailed&#xD;
      clinical profile of each patient, along with omics data, which will be analyzed using&#xD;
      artificial intelligence algorithms, and their results will be implemented in the form of new&#xD;
      recommendations of care for high-risk patients and those already suffering from diabetes.&#xD;
&#xD;
      The study will be conducted prospectively. The project participants will be patients with&#xD;
      diabetes, patients at high risk of developing diabetes and a control group of normoglycemic&#xD;
      patients who will participate in study visits at the Clinical Research Center of the Medical&#xD;
      University of Bialystok.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this project is to create a registry of diabetic patients, containing a detailed&#xD;
      clinical profile of each patient, along with omics data, which will be analyzed using&#xD;
      artificial intelligence algorithms, and their results will be implemented in the form of new&#xD;
      recommendations of care for high-risk patients and those already suffering from diabetes.&#xD;
&#xD;
      The study will be conducted prospectively. The project participants will be patients with&#xD;
      diabetes, patients at high risk of developing diabetes and a control group of normoglycemic&#xD;
      patients who will participate in study visits at the Clinical Research Center of the Medical&#xD;
      University of Bialystok.&#xD;
&#xD;
      As part of the project, each patient will take part in one visit at the research center.&#xD;
      During the visit, each patient will undergo a detailed medical interview regarding the&#xD;
      current health condition, the course of previously diagnosed diseases, family history,&#xD;
      physical activity and diet. In addition, venous blood will be taken for each patient, from&#xD;
      which the basic metabolic parameters will be determined (including glucose, lipid profile,&#xD;
      HbA1c, AST, ALT, GGTP, electrolytes, blood count with smear, presence of antibodies against&#xD;
      beta-cell antigens, TSH, ACTH) and omics analyzes will be performed (including genotyping and&#xD;
      sequencing of DNA, transcriptomics, metabolomics, proteomics and lipidomics). Additionally&#xD;
      from each patient saliva, urine, stool sample, and skin and nasal swabs to assess the&#xD;
      microbiome, will be collected. Each patient will also receive a detailed body composition&#xD;
      analysis using bioimpedance and densitometry (DXA) and grip strength analysis. Non-diabetic&#xD;
      patients will also undergo an oral glucose load test (OGTT).&#xD;
&#xD;
      In addition, patients who give additional consent will be able to participate in additional&#xD;
      visits including abdominal MR imaging with the assessment of liver steatosis, a biopsy of the&#xD;
      vastus lateralis muscle, cardio-pulmonary exercise test, metabolic clamp (euglycemic -&#xD;
      hyperinsulinemic) and glycemia assessment using the continuous glucose monitoring system (&#xD;
      CGM).&#xD;
&#xD;
      As part of the project, we plan for follow-up each participant with re-visits in the study&#xD;
      centre every two years, covering exactly the same schedule of visits as the patient will make&#xD;
      the first time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2099</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2099</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>2 years</time_frame>
    <description>Haemoglobin A1c measured by the high-performance liquid chromatography (HPLC) method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>2 years</time_frame>
    <description>Fasting glucose concentration measured in plasma using the colorimetric method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2-hour glucose</measure>
    <time_frame>2 years</time_frame>
    <description>Glucose concentration at 2-hour of the oral glucose tolerance test, measured in plasma using the colorimetric method - only in non-diabetic subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>2 years</time_frame>
    <description>Fasting insulin concentration measured in plasma using the immunoradiometric assay (IRMA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lean body mass</measure>
    <time_frame>2 years</time_frame>
    <description>Total lean body mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fat mass</measure>
    <time_frame>2 years</time_frame>
    <description>Total body fat mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visceral Adipose Tissue mass</measure>
    <time_frame>2 years</time_frame>
    <description>Visceral adipose tissue mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>2 years</time_frame>
    <description>Total body weight measured using standardized scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Homeostatic model assessment for insulin resistance (HOMA-IR )</measure>
    <time_frame>2 years</time_frame>
    <description>Homeostatic model assessment for insulin resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Homeostatic model assessment of beta cell function (HOMA-beta)</measure>
    <time_frame>2 years</time_frame>
    <description>Homeostatic model assessment of beta cell function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2max</measure>
    <time_frame>2 years</time_frame>
    <description>Maximal oxygen consumption measured during cardio-pulmonary exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides (TG)</measure>
    <time_frame>2 years</time_frame>
    <description>Serum triglycerides concentration measured using colorimetric method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-density lipoprotein cholesterol (HDL)</measure>
    <time_frame>2 years</time_frame>
    <description>Serum high-density lipoprotein cholesterol (HDL) concentration measured using colorimetric method Serum high-density lipoprotein cholesterol (HDL) concentration measured using colorimetric method&#xD;
Serum high-density lipoprotein cholesterol (HDL) concentration measured using colorimetric meth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low-density lipoprotein cholesterol (LDL)</measure>
    <time_frame>2 years</time_frame>
    <description>Serum low-density lipoprotein cholesterol (LDL) concentration measured using colorimetric method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>2 years</time_frame>
    <description>Serum total cholesterol concentration measured using colorimetric method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma metabolome</measure>
    <time_frame>2 years</time_frame>
    <description>plasma metabolites concentrations measured using untargeted metabolomics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal muscle transcriptome</measure>
    <time_frame>2 years</time_frame>
    <description>skeletal muscle gene and smallRNA expressions measured using untargeted transcriptomics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal muscle metabolome</measure>
    <time_frame>2 years</time_frame>
    <description>skeletal muscle metabolites concentrations measured using untargeted metabolomics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma microRNAs</measure>
    <time_frame>2 years</time_frame>
    <description>Expression of circulating smallRNA</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Diabetes</condition>
  <condition>Obesity</condition>
  <condition>PreDiabetes</condition>
  <condition>Dysglycemia</condition>
  <arm_group>
    <arm_group_label>Diabetes</arm_group_label>
    <description>Patients with diagnosed diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prediabetes</arm_group_label>
    <description>Patients with diagnosed prediabetes defined as impaired fasting glucose and/or impaired glucose tolerance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normoglycemia</arm_group_label>
    <description>Patients with normoglycemia, based on the OGTT - normal fasting glucose and normal glucose tolerance</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study - registry</intervention_name>
    <description>Observational study - registry</description>
    <arm_group_label>Diabetes</arm_group_label>
    <arm_group_label>Normoglycemia</arm_group_label>
    <arm_group_label>Prediabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The project participants will be patients with diabetes, patients at high risk of&#xD;
        developing diabetes (prediabetes) and a control group of normoglycemic patients from&#xD;
        Poland.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with diagnosed diabetes (according to the American Diabetes Association&#xD;
             criteria) - diabetes group&#xD;
&#xD;
          -  patients with diagnosed prediabetes (IFG and/or IGT) - prediabetes group&#xD;
&#xD;
          -  patients with normoglycemia (NFG and NGT) - normoglycemia group&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  drug addiction&#xD;
&#xD;
          -  severe psychiatric disorders&#xD;
&#xD;
          -  patients with gestational diabetes mellitus&#xD;
&#xD;
          -  patients unable to give informed consent, legally incompetent or incapable to comply&#xD;
             with the study terms and conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lukasz Szczerbinski, MD, PhD</last_name>
    <phone>+48858318150</phone>
    <email>lukasz.szczerbinski@umb.edu.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Centre, Medical University of Bialystok</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukasz Szczerbinski, MD, PhD</last_name>
      <phone>+48 85 831 81 50</phone>
      <email>lukasz.szczerbinski@umb.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Kretowski, Prof., MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukasz Szczerbinski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes registry</keyword>
  <keyword>prediabetes registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

